Young-Won Kwon

Young-Won Kwon

Auto-generated profile, based on publicly available information

Young-Won Kwon

Department of Internal Medicine, Soonchunhyang University Hospital, Cheonan 31151, Republic of Korea

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2017 in Frontiers in Cellular Neuroscience
Verified
Journal Article
Open access
YKYoung-Won Kwon
Young-Won Kwon
SCSo Yeong Cheon
So Yeong Cheon
SPSung Yun Park
Sung Yun Park
JSJuhyun Song
Juhyun Song
JLJu-Hee Lee
Ju-Hee Lee
Microglia are the resident macrophages in the central nervous system (CNS) and play essential roles in neuronal homeostasis and neuroinflammatory pathologies. Recently, microglia have been shown to contribute decisively to neuropathologic processes after ischemic stroke. Furthermore, natural compounds have been reported to attenuate inflammation and pathologies associated with neuroinflammation. Tryptanthrin (indolo[2,1-b]quinazoline-6,12-dione) is a phytoalkaloid with known anti-inflammatory effects in cells. In present study, the authors confirmed middle cerebral artery occlusion (MCAO) injury triggers the activation of microglia in brain tissue, and investigated whether tryptanthrin influences the function of mouse murine BV2 microglia under LPS-induced inflammatory conditions in vitro. It was found tryptanthrin protected BV2 microglia cells against LPS-induced inflammation and inhibited the induction of M1 phenotype microglia under inflammatory conditions. In addition, tryptanthrin reduced the production of pro-inflammatory cytokines in BV2 microglia cells via nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase 1 (HO-1) signaling and NF-κB signaling. The authors suggest that tryptanthrin might alleviate the progress of neuropathologies by controlling microglial functions under neuroinflammatory conditions.

10 December 2021 in Molecules and Cells
Verified
Journal Article
Open access
PDF file
JLJi Ae Lee
Ji Ae Lee
YKYoung-Won Kwon
Young-Won Kwon
HKHye Ri Kim
Hye Ri Kim
NSNari Shin
Nari Shin
HSHyo Jin Son
Hyo Jin Son
OHOnyou Hwang
Onyou Hwang
Ji Ae Lee, Young-Won Kwon, Hye Ri Kim, Nari Shin, Hyo Jin Son, Chan Seong Cheong, Dong Jin Kim, and Onyou Hwang. Mol. Cells 2022;45:134-47. https://doi.org/10.14348/molcells.2021.0074

Verified
Journal Article
Open access
PDF file
WKWon Kim
Won Kim
SLSeul Ki Lee
Seul Ki Lee
YKYoung-Won Kwon
Young-Won Kwon
SCSun Gun Chung
Sun Gun Chung
SKSoo Kim
Soo Kim
Various therapeutic effects of mesenchymal stem cells (MSCs) have been reported. However, the rapid clearance of these cells in vivo, difficulties in identifying their therapeutic mechanism of action, and insufficient production levels remain to be resolved. We investigated whether a pioglitazone pre-treatment of MSCs (Pio-MSCs) would stimulate the proliferation of co-cultured tenocytes. Pioglitazone increased the proliferation of MSCs and enhanced the secretion of VEGF (vascular endothelial growth factor) and collagen in these cells. We then examined the effects of Pio-MSCs on tenocytes using an indirect transwell culture system. A significant increase in tenocyte proliferation and cell cycle progression was observed in these co-cultures. Significant increases were observed in wound scratch closure by tenocytes from a Pio-MSC co-culture. Pio-MSCs also enhanced the secretion of collagen from tenocytes. A higher mRNA level of collagen type 1 (Col 1) and type 3 (Col 3), scleraxis (Scx), and tenascin C (TnC) was found in the tenocytes in Pio-MSC co-cultures compared with monocultured cells or tenocytes cultured with non-treated MSCs. Our results indicate that pioglitazone enhances the therapeutic effects of MSCs on tendon repair.

28 July 2017 in BMC Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
JPJu-Yeon Park
Ju-Yeon Park
YKYoung-Won Kwon
Young-Won Kwon
SLSoo Chil Lee
Soo Chil Lee
SPSun-Dong Park
Sun-Dong Park
JLJu-Hee Lee
Ju-Hee Lee
SC-E1 is a novel herbal formula consisting of five oriental medicinal herbs used frequently in traditional herbal medicine for the treatment of inflammatory diseases in Korea. This study examined the effects of SC-E1 on lipopolysaccharide (LPS)-stimulated macrophages and the molecular mechanism involved. The cytotoxic effect of the SC-E1 extract was evaluated in RAW 264.7 cells by MTT assay. The effects of SC-E1 on the free radical scavenging and generation of intracellular reactive oxygen species were measured using DPPH and DCFH-DA, respectively. The effects of SC-E1 on the production of pro-inflammatory cytokines, inflammatory mediators, and related products were determined by ELISA and western blotting. The molecular mechanism and the nuclear translocation of nuclear factor-kappa B (NF-κB) and NF-E2-related factor 2 (Nrf2) were examined by western blot analysis and immunocytochemistry. SC-E1 exhibited strong anti-oxidant activity and inhibited LPS-induced NO secretion as well as iNOS expression and the production of pro-inflammatory cytokines, without affecting the cell viability. SC-E1 also suppressed the LPS-induced NF-κB activation and the mitogen-activated protein kinase (MAPK) pathway. Moreover, SC-E1 induced heme oxygenase-1 (HO-1) expression via the nuclear translocation of Nrf2. The inhibitory effects of SC-E1 on the production of pro-inflammatory cytokines were abrogated by treatment with SnPP, an HO-1 inhibitor. These results suggest that SC-E1 exerts its anti-oxidant and anti-inflammatory effects through the inhibition of NF-κB and MAPK as well as Nrf2-mediated HO-1 induction in macrophages. These findings provide evidences for SC-E1 to be considered as a new prescription for treating inflammatory diseases.

30 August 2017 in Phytotherapy Research
Verified
Journal Article
Open access
PDF file
JLJu-Hee Lee
Ju-Hee Lee
YSYoung Hoon Son
Young Hoon Son
YKYoung‐Won Kwon
Young‐Won Kwon
SPSung Yun Park
Sung Yun Park
BKByung‐Soo Koo
Byung‐Soo Koo
SJSeung Hyun Jung
Seung Hyun Jung
An H9 is a formula of nine medicinal herbs derived from Osuyubujaijung‐tang, a traditional Korean prescription for Soeumin constitution. In our previous study, H9 showed anticancer effects against breast cancer and non‐small‐cell lung cancer. However, the underlying mechanisms of these effects have not yet been elucidated. In this study, we investigated the effects of H9, both alone and in combination with trastuzumab, on breast cancer cells and sought to elucidate the mechanisms involved. H9 suppressed the proliferation of human breast cancer cells, induced arrest of the cell cycle at the G0/G1 phase, and caused mitochondrial dysfunction and apoptosis. In addition, H9 induced the activation of AMPK and inhibited the HER2‐PI3K/Akt signaling pathway. Furthermore, H9 attenuated hypoxia‐induced HIF‐1α and VEGF, resulting in decreased migration and invasion of breast cancer cells. Compared with treatment with either drug alone, co‐treatment with H9 and trastuzumab significantly inhibited the growth of BT‐474 cells through induction of apoptosis. These results suggest that H9 should be considered as a potent anticancer agent that targets the HER2‐PI3K/Akt pathway, and the combination of H9 with trastuzumab should be considered as a new therapeutic regimen for treating breast cancer. Copyright © 2017 John Wiley & Sons, Ltd.

1 May 2021 in Journal of Integrative Medicine
Verified
Journal Article
Closed access
JPJu-Yeon Park
Ju-Yeon Park
YKYoung-Won Kwon
Young-Won Kwon
SKSun-Ah Kim
Sun-Ah Kim
SPSun-Dong Park
Sun-Dong Park
CKChang-Hyun Kim
Chang-Hyun Kim
JLJu-Hee Lee
Ju-Hee Lee